DRKS00027982招募中不适用
WAYLIVRA® Post-Authorisation Safety Study (PASS) and Product Registry - WAYLIVRA PASS
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •1. Adult patients (= 18-years-old) prescribed WAYLIVRA™ in accordance with the approved Summary of Product Characteristics.
- •2. Treated in Germany.
- •3. Have provided written informed consent.
排除标准
- •Patients for whom WAYLIVRA is not advised including:
- •Patients with chronic or unexplained thrombocytopenia. Treatment should not be initiated in patients with thrombocytopenia (platelet count < 140 × 109/L).
- •Patients with hypersensitivity to the active substance or to any of the following excipients:
- •o Sodium hydroxide (for pH adjustment).
- •o Hydrochloric acid (for pH adjustment).
研究者
相似试验
进行中（未招募）
不适用
Post-authorization safety study to prospectively monitor the incidence of relevant drug-related adverse events and EPO-related lack of efficacy among CKD subjects receiving HX575 recombinant human erythropoietin alfa i.v. - NDEUCTR2007-005728-34-ITHEXAL BIOTECH1,500
招募中
1 期
A Phase IV, Post-Authorization Safety Study to Investigate the Long-Term Safety of lutetium (177Lu) vipivotide tetraxetan in Adult Participants with Prostate CancerMedDRA version: 20.0Level: SOCClassification code: 10029104Term: Neoplasms benign malignant and unspecified (incl cysts and polyps) Class: 2Prostate cancerCTIS2023-503208-94-00ovartis Pharma AG704
Unknown
4 期
Post marketing study to evaluate the side effects and bleeding controlling effectiveness of RECOMBINATE (Factor VIII) drug.CTRI/2011/11/002135Baxter India Pvt Ltd50
进行中（未招募）
不适用
Post authorisation safety study to prospectively monitor the incidence of relevant drug-related adverse events and EPO-related lack of efficacy among CKD subjects receiving HX575 recombinant human erythropoietin alfa i.v. - not applicableChronic kidney disease subjects with or without dialysis treatment and requiring i.v. ESA treatmentMedDRA version: 9.1Level: LLTClassification code 10009120Term: Chronic renal failure anaemiaEUCTR2007-005728-34-ATHexal Biotech ForschungsGmbH1,500
进行中（未招募）
不适用
Post authorisation safety study to prospectively monitor the incidence of relevant drug-related adverse events and EPO-related lack of efficacy among CKD subjects receiving HX575 recombinant human erythropoietin alfa i.v. - not applicableChronic kidney disease subjects with or without dialysis treatment and requiring i.v. ESA treatmentMedDRA version: 9.1Level: LLTClassification code 10009120Term: Chronic renal failure anaemiaEUCTR2007-005728-34-DEHexal AG1,500